Bristol Says It’s Ready For PD-1 Competition In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Opdivo sales got out of the gate slowly, but Bristol sees encouraging trends – and has a validated diagnostic for the PD-L1 therapy at the ready, if needed.
You may also be interested in...
Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
Doc On Call? Cosmetic Manufacturers May Need M.D. On Retainer Under MoCRA
Cosmetic manufacturers may need to retain a medical professional to determine if adverse events they receive are minor or serious given the looming deadline for maintaining records and reporting serious adverse events to the US FDA, says Locke Lord partner David Abramowitz.